New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareCerebrolysin vs Adamax

Cerebrolysin vs Adamax

Side-by-side comparison of key properties, dosing, and research.

Cognitive EnhancementAnti-Aging & Longevity
Cerebrolysin
Cognitive Enhancement
Adamax
Summary
Cerebrolysin is a porcine brain-derived neuropeptide complex that mimics the action of endogenous neurotrophic factors (BDNF, NGF, GDNF, NT-3). It promotes neurogenesis, neuroprotection, and synaptic plasticity, and is approved in many countries for stroke, traumatic brain injury, and Alzheimer's disease.
Adamax is a synthetic neuropeptide related to brain-derived neurotrophic factor (BDNF) signaling pathways. It is explored for cognitive enhancement, neuroprotection, and mood support, with proposed mechanisms involving TrkB receptor activation and enhancement of neuroplasticity similar to endogenous BDNF.
Half-Life
Variable for the complex; individual peptide fractions: minutes to hours
Estimated 1-3 hours (short; peptide degradation)
Admin Route
IV, IM
Subcutaneous, Intranasal (research)
Research
Typical Dose
5–10 mL
200-400 mcg per dose
Frequency
Daily for 10–20 days
Once daily or every other day
Key Benefits
  • Promotes neurogenesis and synaptic plasticity
  • Approved for stroke rehabilitation (accelerates recovery)
  • Alzheimer's disease: slows progression and improves cognition
  • Traumatic brain injury recovery
  • Enhances memory and executive function
  • Neuroprotection against oxidative stress and excitotoxicity
  • Anti-amyloid and anti-tau effects
  • Mood improvement and reduced anxiety
  • Proposed enhancement of learning and memory consolidation
  • Neuroprotective via BDNF-TrkB pathway support
  • May improve mood and resilience to stress
  • Potential support for neurogenesis
  • Cognitive clarity and focus enhancement (reported anecdotally)
  • Explored for neurodegeneration and age-related cognitive decline
Side Effects
  • Generally well tolerated
  • Mild nausea and dizziness (IV infusion)
  • Headache at initiation
  • Rare: agitation (usually at very high doses)
  • +2 more
  • Limited human safety data; largely anecdotal reports
  • Possible headache or mild overstimulation
  • Sleep disruption with late-day dosing
  • Unknown long-term safety profile
Stacks With